TP53BP1 and breast carcinoma: 53BP1 deletion or mutations thus allow repair and therefore resistance in BRCA1 defective tumor cells, which is a proposed prominent resistance pathway in breast cancers (Bouwman et al., 2010; Bunting et al., 2010).